Millions more children to be protected from meningitis with new vaccine

23 Dec 2019
Millions more children to be protected from meningitis with new vaccine

The World Health Organization has approved a new vaccine which, according to Médecins Sans Frontières (MSF) will protect 55 million children from poorer countries from contracting pneumonia, the biggest childhood killer, and which can result in meningitis and septicaemia.

The bacteria which causes pneumonia is estimated to cause nearly 400,000 deaths each year in children under 5 worldwide.

The new vaccine, called Pneumosil, will be manufactured by the Serum Institute of India.  Pneumosil is much cheaper than the existing vaccines, which means immunisations are now within the reach of millions of children in low and middle-income countries who are currently unprotected from death and disability which can result from pneumococcal meningitis.

MRF’s goal is to see fewer people get meningitis and septicaemia, and to do this effective vaccines should be in place everywhere to protect people most at risk.  Widening worldwide access to life-saving vaccines is a critical step forward on the path to defeat meningitis by 2030. 

The vaccine is listed on WHO’s prequalification site and the news was announced by MSF and PATH.

£160/€190/$214 decodes the genetic information in a sample of meningococcal bacteria. This information has helped us track new forms of meningitis and campaign to introduce new vaccines to protect people.
There are safe and effective vaccines available that that protect against the most common causes of life-threatening bacterial meningitis and septicaemia
Every day we hear from individuals and families affected by or at risk of meningitis and septicaemia. By listening to their stories, and with nearly 30 years of experience, we have developed a good understanding of what they need to be protected, treated and supported. This strategy is written for them, from their perspective, so that no one is left behind.
We fund research into the prevention, detection and treatment of meningitis and sepsis
Media contact
Rob Dawson - Director of Advocacy, Communications and Support
Tel: 0333 405 6262
Share this